A few weeks ago, I mentioned that this proposed new indication was voted down by the Advisory Committee at FDA -- and wondered aloud whether an ex-Merck officer's new role as Senior Counsel to the Commissioner might lead to mischief, in the form of an approval at the full Commission level.
I can safely report that it has not.
The full Commission has voted not to grant the label expansion. I'd guess that just cost Kenilworth about an annual $50 million in sales in the US. Immaterial, but a strange end to a twisted ten year tale.
So it goes.
Onward.
Monday, February 15, 2016
Merck Gets A "No" From FDA -- On Latest Label Expansion From IMPROVE-IT Data
Subscribe to:
Post Comments (Atom)
2 comments:
It would be a wonderful world if we could all trust- with certainty -that each of our lives and end-health were guarded from the interests of individuals with bottomless pockets. What a world to imagine!
Smiling for now...
Indeed -- but sadly that world sails the far horizon, from where I sit... Still there are so many reasons to smile! Great comment!
Namaste -- do stop back by...
Post a Comment